<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869360</url>
  </required_header>
  <id_info>
    <org_study_id>CNS-2016-293</org_study_id>
    <nct_id>NCT02869360</nct_id>
  </id_info>
  <brief_title>Correlation Between PET and Advanced MRI in Multiple Sclerosis</brief_title>
  <official_title>PILOT STUDY OF POSITRON EMISSION TOMOGRAPHY (PET) IMAGING: CORRELATIONS WITH ADVANCED MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TEVA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditional Magnetic Resonance Imaging (MRI) in Multiple Sclerosis (MS) has enabled
      clinicians to measure disease activity but there are inherent limitations.
      Clinical/radiographic dissociation can be seen in some patients and the abnormalities are
      not specific.

      This pilot study is an opportunity to determine the relationship between quantitative
      advanced MRI measures and OCT with PET measurements of microglial activation and myelin
      health.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Brain PBR28 binding</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesional PiB binding</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myelin Water Imaging</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MR Spectroscopy (Total NAA, NAA/Cr, mI)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography (RNFL thickness)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple Sclerosis patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        4 untreated RRMS, 4 untreated SPMS, 4 untreated PPMS patients, 4 healthy controls and 4 GA
        40mg TIW
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Multiple Sclerosis according to the 2011 McDonald criteria.

          -  Aged 18 to 60

          -  High or mixed affinity binder to rs6971 TSPO polymorphism

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Suffering from an unstable medical condition

          -  Have a neurological or ocular disorder other than MS

          -  Any contra-indications to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 30, 2016</lastchanged_date>
  <firstreceived_date>August 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Philippe Beauchemin</investigator_full_name>
    <investigator_title>Clinical Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
